Yin Wesley, Horblyuk Ruslan, Perkins Julia Jane, Sison Steve, Smith Greg, Snider Julia Thornton, Wu Yanyu, Philipson Tomas J
University of California, Los Angeles (Dr Yin); Pfizer, Inc., New York, New York (Dr Horblyuk, Dr Perkins, Mr Smith); Precision Health Economics (Dr Sison, Dr Snider, Dr Wu), Los Angeles, California; and University of Chicago, Chicago, Illinois (Dr Philipson).
J Occup Environ Med. 2017 Feb;59(2):198-204. doi: 10.1097/JOM.0000000000000936.
Determine workplace productivity losses attributable to breast cancer progression.
Longitudinal analysis linking 2005 to 2012 medical and pharmacy claims and workplace absence data in the US patients were commercially insured women aged 18 to 64 diagnosed with breast cancer. Productivity was measured as employment status and total quarterly workplace hours missed, and valued using average US wages.
Six thousand four hundred and nine women were included. Breast cancer progression was associated with a lower probability of employment (hazard ratio [HR] = 0.65, P < 0.01) and increased workplace hours missed. The annual value of missed work was $24,166 for non-metastatic and $30,666 for metastatic patients. Thus, progression to metastatic disease is associated with an additional $6500 in lost work time (P < 0.05), or 14% of average US wages.
Breast cancer progression leads to diminished likelihood of employment, increased workplace hours missed, and increased cost burden.
确定因乳腺癌进展导致的工作场所生产力损失。
对2005年至2012年美国商业保险女性患者（年龄在18至64岁之间，被诊断患有乳腺癌）的医疗和药房索赔以及工作场所缺勤数据进行纵向分析。生产力通过就业状况和错过的季度总工作时长来衡量，并使用美国平均工资进行估值。
纳入了6409名女性。乳腺癌进展与就业概率降低（风险比[HR]=0.65，P<0.01）以及工作场所错过的时长增加有关。非转移性患者错过工作的年度价值为24166美元，转移性患者为30666美元。因此，进展为转移性疾病与额外损失6500美元的工作时间相关（P<0.05），占美国平均工资的14%。
乳腺癌进展导致就业可能性降低、工作场所错过的时长增加以及成本负担加重。
